Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income towards Common Stockholders (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Net Income towards Common Stockholders for 4 consecutive years, with -$21.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 67.53% to -$21.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$107.3 million, a 47.57% increase, with the full-year FY2025 number at -$107.3 million, down 12.44% from a year prior.
  • Net Income towards Common Stockholders was -$21.3 million for Q4 2025 at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $35.8 million in Q3 2024 to a low of -$112.4 million in Q2 2024.
  • A 4-year average of -$40.2 million and a median of -$39.0 million in 2022 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: skyrocketed 177.66% in 2024, then crashed 154.94% in 2025.
  • Day One Biopharmaceuticals' Net Income towards Common Stockholders stood at -$40.1 million in 2022, then tumbled by 35.91% to -$54.5 million in 2023, then fell by 20.54% to -$65.7 million in 2024, then skyrocketed by 67.53% to -$21.3 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Net Income towards Common Stockholders are -$21.3 million (Q4 2025), -$19.7 million (Q3 2025), and -$30.3 million (Q2 2025).